Jinchuan International (02362): Hongri Capital appointed as independent financial advisor.
Jinchuan International (02362) has announced that Hongri Capital Limited, a licensed corporation under the Securities and Futures Ordinance of Hong Kong Chapter 571 to conduct Type 1 (securities trading) and Type 6 (providing advice on corporate finance) regulated activities, has been appointed as an independent financial adviser (independent financial adviser) with the approval of the independent director committee in accordance with Rule 2.1 of the Takeovers Code, to provide advice to the independent director committee on certain offers (especially whether the partial offer is fair and reasonable, and whether the partial offer should be accepted).
JINCHUAN INTL (02362) announced that Red Sun Capital Limited (a licensed corporation under the Securities and Futures Ordinance of Hong Kong, capable of conducting Type 1 (dealing in securities) and Type 6 (advising on corporate finance) regulated activities) has been appointed as the independent financial advisor (IFA) by the Independent Board Committee in accordance with Rule 2.1 of the Takeover Code, to provide advice to the Independent Board Committee on certain offers (particularly on whether the offers are fair and reasonable and whether the offers should be accepted).
Related Articles
Pharmaron Beijing (03759) plans to build a project in Shaoxing that would produce 200 tons of pharmaceutical intermediates and APIs annually.
CONSUN PHARMA (01681) plans to carry out a share buyback program.
Pharmaron Beijing (03759) plans to invest approximately 2 billion yuan to establish a new drug commercial production and CDMO research and development production service base in Qiantang District, Hangzhou City.
Pharmaron Beijing (03759) plans to build a project in Shaoxing that would produce 200 tons of pharmaceutical intermediates and APIs annually.
CONSUN PHARMA (01681) plans to carry out a share buyback program.
Pharmaron Beijing (03759) plans to invest approximately 2 billion yuan to establish a new drug commercial production and CDMO research and development production service base in Qiantang District, Hangzhou City.
